The latest update is out from ATAI Life Sciences ( (ATAI) ).
On February 12, 2025, atai Life Sciences announced the pricing of a public offering of 26,190,477 common shares at $2.10 per share, expected to close on February 14, 2025. The estimated net proceeds of approximately $51.4 million will be used for general corporate purposes and to advance its clinical development programs. Additionally, Beckley Psytech, in which atai has a strategic investment, announced positive results from studies on ELE-101 and BPL-003, showing significant improvements in mental health conditions such as Major Depressive Disorder and Alcohol Use Disorder.
More about ATAI Life Sciences
atai Life Sciences is a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders. The company is dedicated to developing novel, evidence-based therapeutics to treat depression, anxiety, and other mental health disorders.
YTD Price Performance: 59.38%
Average Trading Volume: 2,348,646
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $427.9M
For detailed information about ATAI stock, go to TipRanks’ Stock Analysis page.